Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eltrombopag - Novartis

Drug Profile

Eltrombopag - Novartis

Alternative Names: 497115; Eltrombopag olamine; Promacta; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 15 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer French Innovative Leukemia Organisation; GlaxoSmithKline; Novartis; Technische Universitat Dresden; US Department of Health and Human Services
  • Class Antianaemics; Benzoates; Hydrazines; Pyrazoles; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase II Acute myeloid leukaemia
  • Research Radiation injuries
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 28 Jan 2019 GlaxoSmithKline terminates the phase II/III SQUELCH-C trial for Thrombocytopenia (in patients with HCV infection) in USA, as interferon use for hepatitis C plummeted, eliminating the need for study drug (PO) (NCT01821625)
  • 18 Jan 2019 GlaxoSmithKline and M.D. Anderson Cancer Center terminates phase II trial in Myelodysplastic syndrome in USA (NCT02010645)
  • 17 Dec 2018 Novartis initiates enrolment in a phase II trial in Spain (PO) (NCT03718533)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top